CALCA and migraine disorder: Because monoclonal antibodies targeting either the CGRP ligand or receptor are used clinically for migraine prevention (Tso & Goadsby, 2017; Bhakta et al, 2021), we treated A549-bearing immunodeficient mice with either murine monoclonal antibody against CGRP (anti-CGRP Ab) or isotype control antibody.